Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 5/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 5/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2929945 | 0.96 | ALDH1A1 (0.48) | LMNAALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL16794181 | 0.83 | DRD3 (0.52) | LMNAALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL3549356 | 0.79 | KDM4E (0.41) | LMNAALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL15017805 | 0.79 | ALDH1A1 (0.43) | LMNAALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL2929584 | 0.79 | KDM4E (0.41) | LMNAALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL29777592 | 0.78 | DRD3 (0.54) | LMNAALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL16814051 | 0.78 | NTRK1 (0.40) | ALDH1A1KDM4EKMT2AHPGDMAPK1 | |
| SCHEMBL29777576 | 0.77 | DRD3 (0.53) | LMNAALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL18183915 | 0.76 | SMN1; SMN2 (0.44) | ALDH1A1KDM4EKMT2AHPGDHSD17B10 | |
| SCHEMBL1208389 | 0.76 | LMNA (0.45) | LMNAALDH1A1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108948019-B | Focal adhesion kinase inhibitors and uses thereof | 广东东阳光药业有限公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-2844658-B1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | GENENTECH INC (US) | 2019-03-20 | — | — | EP | disclosed |
| EP-3080103-B1 | BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY | BIOGEN MA INC (US) | 2018-04-18 | — | — | EP | disclosed |
| US-9212186-B2 | Bicyclic pyrazole LRRK2 small molecule inhibitors | GENENTECH, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| EP-2844658-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | F. Hoffmann-La Roche AG (CH) | 2015-03-11 | — | — | EP | disclosed |
| US-20150051201-A1 | BICYCLIC PYRAZOLE LRRK2 SMALL MOLECULE INHIBITORS | GENENTECH, INC. (US) | 2015-02-19 | — | — | US | disclosed |
| WO-2013164323-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-11-07 | — | — | WO | disclosed |
| US-20120252853-A1 | Positive allosteric modulators of nicotinic acetylcholine receptor | H. LUNDBECK A/S (DK) | 2012-10-04 | — | — | US | disclosed |
| WO-2012131031-A1 | NEW POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR | H. LUNDBECK A/S (DK) | 2012-10-04 | — | — | WO | disclosed |
| US-20120252853-A1 | Positive allosteric modulators of nicotinic acetylcholine receptor | H. LUNDBECK A/S (DK) | 2012-10-04 | — | — | US | disclosed |
| US-7276611-B2 | Process for synthesizing beta-lactamase inhibitor intermediates | WYETH HOLDINGS CORPORATION (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276611-B2 | Process for synthesizing beta-lactamase inhibitor intermediates | WYETH HOLDINGS CORPORATION (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276611-B2 | Process for synthesizing beta-lactamase inhibitor intermediates | WYETH HOLDINGS CORPORATION (US) | 2007-10-02 | — | — | US | disclosed |
| CN-1823074-A | Process for synthesizing beta-lactamase inhibitor intermediates | WYETH CORP (US) | 2006-08-23 | — | — | CN | disclosed |
| EP-1626972-A1 | PROCESS FOR SYNTHESIZING ß-LACTAMASE INHIBITOR INTERMEDIATES | Wyeth Holdings Corporation (US) | 2006-02-22 | — | — | EP | disclosed |
| EP-1626975-A2 | PROCESS FOR SYNTHESIZING ß-LACTAMASE INHIBITOR IN INTERMEDIATES | Wyeth Holdings Corporation (US) | 2006-02-22 | — | — | EP | disclosed |
| WO-2004104006-A2 | PROCESS FOR SYNTHESIZING β-LACTAMASE INHIBITOR IN INTERMEDIATES | WYETH HOLDINGS CORPORATION (US) | 2004-12-02 | — | — | WO | disclosed |
| US-20040242874-A1 | Process for synthesizing beta-lactamase inhibitor intermediates | WYETH HOLDINGS CORPORATION | 2004-12-02 | — | — | US | disclosed |
| WO-2004104008-A1 | PROCESS FOR SYNTHESIZING β-LACTAMASE INHIBITOR INTERMEDIATES | WYETH HOLDINGS CORPORATION (US) | 2004-12-02 | — | — | WO | disclosed |
| US-20040229324-A1 | Production of bicyclic-heteroaryl-2-carboxylic acids by selective enzymatic hydrolysis of a mixture of positional esters | WYETH HOLDINGS CORPORATION | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051201-A1 | BICYCLIC PYRAZOLE LRRK2 SMALL MOLECULE INHIBITORS | LRRK2, PARK7, PINK1 | LMNA 3588/4885ALDH1A1 2479/4885KDM4E 3741/4885 |
| US-20040229324-A1 | Production of bicyclic-heteroaryl-2-carboxylic acids by selective enzymatic hydrolysis of a mixture of positional esters | COASY, CES2, CES1 | LMNA 2646/4885ALDH1A1 438/4885KDM4E 598/4885 |
| US-20040242874-A1 | Process for synthesizing beta-lactamase inhibitor intermediates | COASY, DCXR, MGAM | LMNA 266/4885ALDH1A1 541/4885KDM4E 612/4885 |
| US-20120252853-A1 | Positive allosteric modulators of nicotinic acetylcholine receptor | CHRNG, CHRNA7, CHRNA2 | LMNA 3217/4885ALDH1A1 3647/4885KDM4E 2085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.